Publications by authors named "Marya F Chaney"

Claim this Profile
B
BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.
Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag, Luis de la Cruz Merino, Eduardo Castañón Álvarez, Marya F Chaney

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.
Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag, Luis de la Cruz Merino, Eduardo Castañón Álvarez, Marya F Chaney

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115.
Caroline Robert, Brian Gastman, Helen Gogas, Piotr Rutkowski, Georgina V Long, Marya F Chaney

Eur J Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers.
Samuel J Klempner, Johanna C Bendell, Victoria Meucci Villaflor, Laura LaNiel Tenner, Stacey M Stein, Marya F Chaney

Mol Cancer Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.
Jin Won Youn, Soo-Young Hur, Jung Won Woo, Yong-Man Kim, Myong Cheol Lim, Marya F Chaney

Lancet Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials.
Emmett V Schmidt, Michael J Chisamore, Marya F Chaney, Marie E Maradeo, James Anderson

JAMA Netw Open· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis